Clinical Trials
Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma
Abramson et alThe Lancet Hematology

In the open-label, randomized controlled phase 2–3 ALLIANCE A051701 trial evaluating newly diagnosed double-hit lymphomas, the addition of venetoclax to dose-adjusted EPOCH-R (DA-EPOCH-R) resulted in excess mortality, prompting early study closure. Despite the premature termination, robust patient accrual demonstrated that prospective, multicenter clinical trials are feasible in this high-risk patient population. Additionally, outcomes observed in the DA-EPOCH-R arm provide a benchmark for future prospective research in double-hit lymphoma.
Key Takeaways
- Adding venetoclax to DA-EPOCH-R in patients with newly diagnosed double-hit lymphoma resulted in excess mortality, prompting early closure of the phase 2–3 ALLIANCE A051701 trial.
- Outcomes observed in the DA-EPOCH-R control arm establish a clinical benchmark for future prospective multicenter double-hit lymphoma trials.
Read the original sourceThe Lancet Hematology
